Develop a new antibody to enhance tumor treatment
DEVELOP A NONCOMPETITIVE MONOCLONAL ANTI-CD25
This study is testing a new treatment for certain types of cancer that combines a special antibody with a light-activated therapy to help your immune system fight tumors better, and it's designed for patients who are looking for more effective options in their cancer care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Leidos Biomedical Research, INC. NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project ID | NIH-10377880 on NIH RePORTER |
What this research studies
This research focuses on creating a monoclonal antibody that targets CD25, a marker found on regulatory T-cells, to improve the effectiveness of a novel cancer treatment called Photoimmunotherapy (PIT). PIT involves injecting an antibody conjugated to a photoabsorber that accumulates in tumors and is activated by near-infrared light to kill cancer cells. The study aims to enhance the immune response against tumors by combining this treatment with the new anti-CD25 antibody, potentially leading to better outcomes for patients with certain types of cancer. The research is currently in the advanced stages, with initial human testing in Phase 3 trials expected to lead to approval soon.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that express CD25 and are undergoing treatment with Photoimmunotherapy.
Not a fit: Patients with tumors that do not express CD25 or those not eligible for Photoimmunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve cancer treatment outcomes by enhancing the immune response against tumors.
How similar studies have performed: Other research has shown promising results with similar approaches, particularly in enhancing immune responses in cancer therapies.
Where this research is happening
Frederick, United States
- Leidos Biomedical Research, INC. — Frederick, United States (Active)
Researchers
- Principal investigator: Dmitrovsky, Ethan — Leidos Biomedical Research, INC.
- Study coordinator: Dmitrovsky, Ethan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.